Hormone replacement therapy (HRT) in women after genital cancer

Maturitas

Volumn 41, Issue SUPPL. 1, 2002, Pages 105-111

  Schindler, Adolf E ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Genital cancer; Hormone replacement therapy; Ovarian function

Indexed keywords

ANTIINFECTIVE AGENT; ESTROGEN; GESTAGEN; HORMONE;

CANCER RECURRENCE; CANCER STAGING; DOSE RESPONSE; ENDOMETRIUM CANCER; FEMALE; FEMALE GENITAL TRACT CANCER; GYNECOLOGY; HORMONE SUBSTITUTION; HUMAN; OVARY CANCER; OVARY FUNCTION; PATIENT CARE; PSYCHOSOMATICS; REVIEW; UTERINE CERVIX CANCER; UTERINE TUBE CARCINOMA; VAGINA CANCER; VULVA CANCER; WELLBEING;

EID: 0037090572     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0378-5122(02)00018-x     Document Type: Review

References (43)

1. Hormone replacement therapy in women treated for gynecological malignancy
2. Hormonal therapy following female genital tract cancer
3. Risk of cancer in women receiving hormone replacement therapy
4. Long-term surveillance of mortality and cancer incidence in women receiving hormone replacement therapy
5. Case-control study of estrogen replacement therapy and risk of cervical cancer
6. Cisplatin radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma
7. Hormone replacement therapy in patients after cervical cancer treatment
8. Use of hormone replacement therapy and adenocarcinomas and squamous cell carcinomas of the uterine cervix
9. Adjuvant progestagen for the treatment of endometrial cancer: Review and meta-analyses of published randomised controlled trials
10. Cancer statistic 2000
11. Endoskopisches Sentinel-Node (ESN)-verfahren zum laparoskopisch assistierten staging des endometriumkarzinoms
12. Effect of exogenous estrogens on postmenopausal women: The epidemiologic evidence
13. Hormone replacement and cancer
14. Risk of endometrial cancer in relation to use of low-dose, unopposed estrogens
15. Effects of various types and dosages of progestogens on the postmenopausal endometrium
16. Therapie mit gestagenen bei hyperplastischen veränderungen des endometriums
17. Hormone replacement therapy and endometrial cancer risk: A meta-analysis
18. Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy-long-term follow up of a Swedish cohort
19. Progestagen supplementation of exogenous oestrogens and risk of endometrial cancer
20. Estrogens, progesterone, and endometrial cancer
21. Estrogen replacement therapy and endometrial cancer risk: Unresolved issues
22. Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40
23. Estrogen replacement therapy following treatment for stage I endometrial carcinoma
24. Estrogen replacement therapy: Is previously treated cancer a contraindication?
25. Long-term follow-up of estrogen replacement therapy in endometrial cancer patients
26. ERT for survivors of endometrial cancer? A new trial will resolve debate
27. Östrogensubstitution in der postmenopause vor und nach behandeltem genital- und mammakarzinom
28. Estrogen replacement in surgical stage I and II endometrial cancer survivors
29. Adjuvant progestagen therapy improves survival in patients with endometrial cancer after hysterectomy. Results of one institution prospective clinical trial
30. Megestrol acetate for the prevention of hot flashes
31. Hormone replacement therapy as a risk factor for epithelial ovarian cancer: Results of a case-control study
32. Incessant ovulation - A factor in ovarian neoplasia?
33. Incessant ovulation and ovarian cancer
34. Hormone replacement therapy and risk of epithelial ovarian cancer
35. Hormone replacement therapy and the risk of epithelial ovarian carcinoma: A meta-analysis
36. Estrogen replacement therapy and fatal ovarian cancer
37. Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women
38. Estrogen-progestin substitution therapy following treatment for ovarian cancer
39. Hormone replacement therapy and survival after surgery for ovarian cancer
40. Estrogen replacement therapy for ovarian carcinoma survivors: A randomized controlled trial
41. Progesterone induces apoptosis and up-regulation of p53 expression in human ovarian carcinoma cell lines
42. Hormonsubstitution bei patientinnen nach primärbehandlung gynäkologischer malignome